Divi's Laboratories — Q3 FY25
Divis Laboratories reported a strong Q3 FY25 with PAT of INR 589 crore, up 64.5% YoY, driven by robust custom synthesis growth and stable generics volumes.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY25
Unit 3 commercial production to start December 2024
Phase-wise production at the 200-acre greenfield Kakinada facility will begin in December 2024, initially focusing on backward integration and regulatory qualifications.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1